Prognostic significance of tumour vascularisation on survival of patients with advanced ovarian carcinoma

Histology and Histopathology

Volumn 24, Issue 4, 2009, Pages 425-435

  Labiche, Alexandre ^a   Elie, Nicolas ^a   Herlin, Paulette ^a   Denoux, Yves ^a,b   Crouet, Hubert ^a,b   Heutte, Natacha ^a   Joly, Florence ^a,b   Héron, Jean François ^a,b   Gaududhon, Pascal ^a   Henry Amar, Michel ^a,b  

^a Biology and Innovative Therapeutics for Ovarian Cancers group   (France)

^b CENTRE FRANÇOIS BACLESSE   (France)

Author keywords

Angiogenesis; Microvessel density; Ovarian cancer; Prognosis; Vascularisation

Indexed keywords

CISPLATIN; PLATINUM COMPLEX;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; CELL DENSITY; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MICROVASCULATURE; OVARY CARCINOMA; OVERALL SURVIVAL; PROGNOSIS; SURVIVAL RATE; TUMOR VASCULARIZATION; ADENOCARCINOMA; DISEASE COURSE; METASTASIS; MIDDLE AGED; MORTALITY; NEOVASCULARIZATION (PATHOLOGY); OVARY TUMOR; PATHOLOGY; VASCULARIZATION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; FEMALE; HUMANS; MICROVESSELS; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PROGNOSIS;

EID: 63449102522     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Alvarez A.A., Krigman H.R., Whitaker R.S., Dodge R.K. and Rodriguez G.C. (1999). The prognostic significance of angiogenesis in epithelial ovarian carcinoma. Clin. Cancer Res. 5, 587-591.
2. Bamberger E.S. and Perrett C.W. (2002). Angiogenesis in epithelian ovarian cancer. Mol. Pathol. 55, 348-359.
3. Belien J.A., Somi S., de Jong J.S., van Diest P.J. and Baak J.P. (1999). Fully automated microvessel counting and hot spot selection by image processing of whole tumour sections in invasive breast cancer. J. Clin. Pathol. 52, 184-192.
4. Birner P., Schindl M., Obermair A., Breitenecker G. and Oberhuber G. (2001). Expression of hypoxia-inducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7, 1661-1668.
5. Darai E., Bringuier A.F., Walker-Combrouze F., Fauconnier A., Couvelard A., Feldmann G., Madelenat P. and Scoazec J.Y. (1998). CD31 expression in benign, borderline, and malignant epithelial ovarian tumors: an immunohistochemical and serological analysis. Gynecol. Oncol. 71, 122-127.
6. Elie N., Kaliski A., Peronneau P., Opolon P., Roche A. and Lassau N. (2007). Methodology for quantifying interactions between perfusion evaluated by DCE-US and hypoxia throughout tumor growth. Ultrasound. Med. Biol. 33, 549-560.
7. Ferrero A., Zola P., Mazzola S., Fuso L., Sarotto I., Ravarino N., Spanu P.G., Jacomuzzi M.E., Carus A.P. and Sismondi P. (2004). Pretreatment serum hemoglobin level and a preliminary investigation of intratumoral microvessel density in advanced ovarian cancer. Gynecol. Oncol. 95, 323-329.
8. Francoise R., Michels J.J., Plancoulaine B. and Herlin P. (2005). Optimal resolution for automatic quantification of blood vessels on digitized images of the whole cancer section. Image Anal. Stereo. (www.wise-t.com/ias) 24, 59-67.
9. Gadducci A., Viacava P., Cosio S., Fanelli G., Fanucchi A., Cecchetti D., Cristofani R. and Genazzani A.R. (2003). Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma. Anticancer Res. 23, 549-556.
10. Gasparini G., Bonoldi E., Viale G., Verderio P., Boracchi P., Panizzoni G.A., Radaelli U., Di Bacco A., Guglielmi R.B. and Bevilacqua P. (1996). Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas. Int. J. Cancer 69, 205-211.
11. Goodheart M.J., Vasef M.A., Sood A.K., Davis C.S. and Buller R.E. (2002). Ovarian cancer p53 mutation is associated with tumor microvessel density. Gynecol. Oncol. 86, 85-90.
12. Heimburg S., Oehler M.K., Papadopoulos T., Caffier H., Kristen P. and Dietl J. (1999). Prognostic relevance of the endothelial marker CD 34 in ovarian cancer. Anticancer Res. 19, 2527-2529.
13. Hlatky L., Hahnfeldt P. and Folkman J. (2002). Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn't tell us. J. Natl. Cancer Inst. 94, 883-893.
14. Hollingsworth H.C., Kohn E.C., Steinberg S.M., Rothenberg M.L. and Merino M.J. (1995). Tumor angiogenesis in advanced stage ovarian carcinoma. Am. J. Pathol. 147, 33-41.
15. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J. and Thun M.J. (2005). Cancer statistics, 2005. CA. Cancer J. Clin. 55, 10-30.
16. Kamat A.A., Kim T.J., Landen C.N., Lu C., Han L.Y., Lin Y.G., Merritt W.M., Thaker P.H., Gershenson D.M., Bischoff F.Z., Heymach J.V., Jaffe R.B., Coleman R.L. and Sood A.K. (2007). Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 67, 281-288.
17. Kaye S.B. (2007). Bevacizumab for the treatment of epithelial ovarian cancer: will this be its finest hour? J. Clin. Oncol. 25, 5150-5152.
18. Kim N.T., Elie N., Plancoulaine B., Herlin P. and Coster M. (2003). An original approach for quantification of blood vessels on the whole tumour section. Anal. Cell. Pathol. 25, 63-75.
19. Losch A., Schindl M., Kohlberger P., Lahodny J., Breitenecker G., Horvat R. and Birner P. (2004). Cathepsin D in ovarian cancer: prognostic value and correlation with p53 expression and microvessel density. Gynecol. Oncol. 92, 545-552.
20. Martin L. and Schilder R. (2007). Novel approaches in advancing the treatment of epithelial ovarian cancer: the role of angiogenesis inhibition. J. Clin. Oncol. 25, 2894-2901.
21. McCluggage W.G., Lyness R.W., Atkinson R.J., Dobbs S.P., Harley I., McClelland H.R. and Price J.H. (2002). Morphological effects of chemotherapy on ovarian carcinoma. J. Clin. Pathol. 55, 27-31.
22. McShane L.M., Altman D.G., Sauerbrei W., Taube S.E., Gion M. and Clark G.M. (2005). REporting recommendations for tumour MARKer prognostic studies (REMARK). Br. J. Cancer 93, 387-391.
23. Mirlacher M., Kasper M., Storz M., Knecht Y., Durmuller U., Simon R., Mihatsch M.J. and Sauter G. (2004). Influence of slide aging on results of translational research studies using immunohistochemistry. Mod. Pathol. 17, 1414-1420.
24. Monk B.J., Choi D.C., Pugmire G. and Burger R.A. (2005). Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancer. Gynecol. Oncol. 96, 902-905.
25. Nakayama K., Kanzaki A., Takebayashi Y., Toi M., Bando H., Nabei T., Miyazaki K. and Fukumoto M. (2001). Different features of angiogenesis between ovarian and breast carcinoma. Cancer Lett. 170, 161-167.
26. Naora H. and Montell D.J. (2005). Ovarian cancer metastasis: integrating insights from disparate model organisms. Nat. Rev. Cancer 5, 355-366.
27. Nico B., Benagiano V., Mangieri D., Maruotti N., Vacca A. and Ribatti D. (2008). Evaluation of microvascular density in tumors: pro and contra. Histol. Histopathol. 23, 601-607.
28. Obermair A., Wasicky R., Kaider A., Preyer O., Losch A., Leodolter S. and Kolbl H. (1999). Prognostic significance of tumor angiogenesis in epithelial ovarian cancer. Cancer Lett. 138, 175-182.
29. Ogawa S., Kaku T., Kobayashi H., Hirakawa T., Ohishi Y., Kinukawa N. and Nakano H. (2002). Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma. Cancer Lett. 176, 111-118.
30. Palmer J.E., Sant Cassia L.J., Irwin C.J., Morris A.G. and Rollason T.P. (2007). Prognostic value of measurements of angiogenesis in serous carcinoma of the ovary. Int. J. Gynecol. Pathol. 26, 395-403.
31. Parkin D.M., Bray F., Ferlay J. and Pisani P. (2005). Global cancer statistics, 2002. CA. Cancer J. Clin. 55, 74-108.
32. Raspollini M.R., Amunni G., Villanucci A., Baroni G., Boddi V. and Taddei G.L. (2004a). Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma. Int. J. Gynecol. Cancer 14, 815-823.
33. Raspollini M.R., Amunni G., Villanucci A., Boddi V., Baroni G., Taddei A. and Taddei G.L. (2004b). COX-2 status in relation to tumor microvessel density and VEGF expression: analysis in ovarian carcinoma patients with low versus high survival rates. Oncol. Rep. 11, 309-313.
34. Rothman K.J. and Boice J.D. (1982). Epidemiologic analysis with a programmable calculator. Boston MA. Epidemiology Resources Inc. pp 1-197.
35. Schoell W.M., Pieber D., Reich O., Lahousen M., Janicek M., Guecer F. and Winter R. (1997). Tumor angiogenesis as a prognostic factor in ovarian carcinoma: quantification of endothelial immunoreactivity by image analysis. Cancer 80, 2257-2262.
36. Schumacher J.J., Dings R.P., Cosin J., Subramanian I.V., Auersperg N. and Ramakrishnan S. (2007). Modulation of angiogenic phenotype alters tumorigenicity in rat ovarian epithelial cells. Cancer Res. 67, 3683-3690.
37. Suhonen K.A., Anttila M.A., Sillanpaa S.M., Hamalainen K.M., Saarikoski S.V., Juhola M. and Kosma V.M. (2007). Quantification of angiogenesis by the Chalkley method and its prognostic significance in epithelial ovarian cancer. Eur. J. Cancer 43, 1300-1307.
38. Vasey P.A. (2003). Resistance to chemotherapy in advanced ovarian cancer: mechanisms and current strategies. Br. J. Cancer 89 (Suppl. 3). S23-S28.
39. Vermeulen P.B., Gasparini G., Fox S.B., Toi M., Martin L., McCulloch P., Pezzella F., Viale G., Weidner N., Harris A.L. and Dirix L.Y. (1996). Quantification of angiogenesis in solid human tumours: an international consensus on the methodology and criteria of evaluation. Eur. J. Cancer 32A, 2474-2484.
40. Vermeulen P.B., Gasparini G., Fox S.B., Colpaert C., Marson L.P., Gion M., Belien J.A., de Waal R.M., Van Marck E., Magnani E., Weidner N., Harris A.L. and Dirix L.Y. (2002). Second international consensus on the methodology and criteria of evaluation of angiogenesis quantification in solid human tumours. Eur. J. Cancer 38, 1564-1579.
41. Wong C., Wellman T.L. and Lounsbury K.M. (2003). VEGF and HIF-1alpha expression are increased in advanced stages of epithelial ovarian cancer. Gynecol. Oncol. 91, 513-517.
42. Yoneda J., Kuniyasu H., Crispens M.A., Price J.E., Bucana C.D. and Fidler I.J. (1998). Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice. J. Natl. Cancer Inst. 90, 447-454.